AZD6234 Advanced Drug Monograph

AZD6234 Medication Report

Name: AZD6234 Name (English): AZD6234

Drug Type: Synthetic peptide Target: Amylin receptor (AMYR) Action: Agonist Mechanism of Action: AZD6234 is a long-acting amylin receptor agonist. It mimics the effects of amylin, a hormone produced by the pancreas that helps to regulate blood glucose levels and appetite. AZD6234 delays gastric emptying, suppresses appetite, and promotes the release of glucagon from the pancreas.

Therapeutic Areas: Endocrinology and Metabolic Disease Active Indication: Obesity, Type 2 Diabetes Mellitus

Clinical Trials: AZD6234 is currently under investigation in several Phase II clinical trials, both as a monotherapy and in combination with other investigational drugs like AZD9550 (a GLP-1/glucagon agonist). These trials are evaluating its efficacy, safety, and tolerability in adults with overweight or obesity, including those with type 2 diabetes.

• ASCEND (D8460C00004): A Phase IIb study evaluating the co-administration of AZD9550 and AZD6234 in participants living with obesity or overweight with co-morbidity.
• APRICUS (D8750C00004): A Phase IIb study evaluating AZD6234 compared to placebo in participants living with obesity or overweight with at least one weight-related comorbidity.
• D8750C00002: A Phase I study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of repeated doses of AZD6234 in participants with overweight or obesity.
• Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist: A Phase II study in this specific population.

Safety and Tolerability: In early Phase I studies, AZD6234 was reported to be well-tolerated in healthy participants, with no deaths or serious adverse events recorded. However, side effects such as nausea, vomiting, and decreased appetite were more common in AZD6234-treated patients compared to placebo.

Originator Organization: AstraZeneca PLC